ArcherDX Announces Close of $55 Million Series C Financing
Proceeds to Support Registration and Launch of STRATAFIDE Pan-Solid Tumor Companion Diagnostic (CDx) and Development of Personal Cancer Monitoring (PCM) Surveillance Platform
Products Designed to Expand Adoption of Personalized Medicine by Enabling Hea... Diagnostics, Venture Capital ArcherDX, Anchored Multiplex PCR, polymerase chain reaction
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news